44. **(newly added)** The composition of claim 43, wherein the interferon -beta-1a fusion protein comprises a portion of an immunoglobulin molecule.

45. **(newly added)** A physiologically active interferon-beta composition comprising a physiologically active interferon-beta-1a comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-40, coupled to a polymer comprising a polyalkylene glycol moiety, wherein the interferon -beta-1a is coupled to the polymer at a site on the interferon-beta-1a that is an N- terminal end, wherein the physiologically active interferon -beta 1a and the polyalkylene glycol moiety are arranged such that the physiologically active interferon-beta-1a in the physiologically active interferon -beta composition has an activity at least 2-fold greater relative to physiologically active interferon-beta-1b, when measured by an antiviral assay.

46. **(newly added)** The composition of claim 45, wherein the interferon-beta-1a is coupled to the polymer at a site by way of a glycan moiety of the interferon-beta-1a.

47. **(newly added)** The composition of claim 45, wherein the interferon-beta-1a is an interferon-beta-1a fusion protein.

48. **(newly added)** The composition of claim 47, wherein the interferon-beta-1a fusion protein comprises a portion of an immunoglobulin molecule.

49. **(newly added)** A physiologically active interferon-beta composition comprising a physiologically active glycosylated interferon-beta-1a comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27-40, N-terminally coupled to a polymer comprising a polyalkylene glycol moiety, wherein the physiologically active interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the physiologically active interferon-beta 1a in the physiologically active interferon-beta composition has equal activity relative to physiologically active interferon-beta lacking said moiety, when measured by an antiviral assay.

50. **(newly added)** The composition of claim 49, wherein the interferon-beta is coupled to the polymer at a site by way of a glycan moiety on the interferon-beta.

51. **(newly added)** The composition of claim 49, wherein the interferon-beta-1a is an interferon beta fusion protein.

52. **(newly added)** The composition of claim 51, wherein the interferon beta fusion protein comprises a portion of an immunoglobulin molecule.

53. **(newly added)** A stable, aqueously soluble, conjugated interferon-beta-1a complex comprising a interferon-beta-1a comprising an amino acid sequence selected from the group consisting of SEQ